✦ LIBER ✦

124 RANDOMIZED PHASE II CLINICAL TRIAL OF INTRATUMORAL INJECTION OF JX-594, A TARGETED MULTI-MECHANISTIC ONCOLYTIC POXVIRUS, IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

✍ Scribed by J. Heo; T. Reid; H.Y. Lim; L. Ruo; C.W. Kim; M. Bloomston; H.C. Chung; B.G. Rhee; R. Patt; C.J. Breitbach; T. Hickman; J.C. Bell; T.H. Hwang; D.H. Kirn

Book ID: 117378212
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 148 KB
Volume: 52
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(10)60126-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Use of a targeted oncolytic poxvirus, JX

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

✍ Byeong-Ho Park; Taeho Hwang; Ta-Chiang Liu; Daniel Y Sze; Jae-Seok Kim; Hyuk-Cha 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 444 KB

A phase I clinical trial of intratumoral

A phase I clinical trial of intratumoral injection of adenovirus encoding interleukin-12 in patients with hepatocellular carcinoma and other advanced gastrointestinal tumors

✍ G.D. Mazzolini; B. Sangro; J. Ruiz; M. Herraiz; J.I. Herrero; J. Quiroga; A. Ben 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 153 KB

A randomized multicenter phase II clinic

A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma

✍ Qinghua Zhou; Xun Sun; Lingyuan Zeng; Jie Liu; Zhirong Zhang 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 151 KB

## From the clinical editor: Intravenous administration of mitoxantrone-loaded polybutylcyanacrylate nanoparticles (dhad-pbca-nps) allows increased cytotoxicity in hepatic tumors and prolonged the median survival periods to 5.46 months compared to 3.23 months in controls.